Trial Profile
A phase II study to evaluate the efficacy and safety using combined monoclonal antibodies, trastuzumab and pertuzumab in subjects with Her-2 overexpressed locally advanced and metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2012 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 07 Mar 2012 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 07 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.